Michelle Outeda-García

8PUBLICATIONS
23CO-AUTHORS
Medical infection agents (incl. prions)Medical bacteriologyPharmacogenomicsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 16, 2026
In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution.

|Feb 19, 2026
Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).

Salud Rodríguez-Pallares, Michelle Outeda-García, Emilio Lence

|Dec 22, 2025
Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants.

Gabriela-Alejandra Báez-Barroso, Arianna Rodríguez-Coello, Juan Carlos Vázquez-Ucha

|May 27, 2025
Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa.

Lucía González-Pinto, María Antonia Gomis-Font, Emilio Lence

|May 20, 2025
The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii.

Michelle Outeda-García, Andrea Garcia-Pose, Paula Guijarro-Sánchez

|Jan 10, 2025
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors.

Michelle Outeda-García, Jorge Arca-Suárez, Emilio Lence

Pageof 2

Frequent Collaborators

8 joint publications

Jorge Arca-Suárez

8 joint publications

Alejandro Beceiro

8 joint publications

Germán Bou

7 joint publications

Juan Carlos Vázquez-Ucha